Literature DB >> 17594330

Cerebral atrophy in Parkinson's disease patients with visual hallucinations.

B Ramírez-Ruiz1, M-J Martí, E Tolosa, M Giménez, N Bargalló, F Valldeoriola, C Junqué.   

Abstract

Although visual hallucinations (VH) are relatively frequent in Parkinson's disease (PD) patients, their neural substrates are only known from neuropathological and functional magnetic resonance studies. The aim of this study was to investigate possible structural brain changes on MRI in non-demented PD patients with VH using voxel-based morphometry. Eighteen PD patients with VH were compared to 20 patients with PD without VH and 21 healthy controls. Compared with both controls and the non-hallucinating PD group, PD patients with VH had grey matter volume reductions in the lingual gyrus and superior parietal lobe. Structural changes in these areas involved in higher visual processing may be important in understanding the VH and visual deficits in PD patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594330     DOI: 10.1111/j.1468-1331.2007.01768.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  46 in total

Review 1.  An update expert opinion on management and research strategies in Parkinson's disease psychosis.

Authors:  Jennifer G Goldman; Christina L Vaughan; Christopher G Goetz
Journal:  Expert Opin Pharmacother       Date:  2011-06-02       Impact factor: 3.889

2.  An update on brain imaging in parkinsonian dementia.

Authors:  Myria Petrou; Vikas Kotagal; Nicolaas I Bohnen
Journal:  Imaging Med       Date:  2012-04

3.  Gray matter atrophy in patients with Parkinson's disease and those with mild cognitive impairment: a voxel-based morphometry study.

Authors:  Jing Zhang; Yun-Ting Zhang; Wei-Dong Hu; Li Li; Guang-Yao Liu; Yu-Ping Bai
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease.

Authors:  James M Shine; Glenda M Halliday; Moran Gilat; Elie Matar; Samuel J Bolitho; Maria Carlos; Sharon L Naismith; Simon J G Lewis
Journal:  Hum Brain Mapp       Date:  2013-06-13       Impact factor: 5.038

5.  Cortical gray and subcortical white matter associations in Parkinson's disease.

Authors:  Nicholas W Sterling; Guangwei Du; Mechelle M Lewis; Steven Swavely; Lan Kong; Martin Styner; Xuemei Huang
Journal:  Neurobiol Aging       Date:  2016-09-28       Impact factor: 4.673

6.  Considering total intracranial volume and other nuisance variables in brain voxel based morphometry in idiopathic PD.

Authors:  Samuel Crowley; Haiqing Huang; Jared Tanner; Qing Zhao; Nadine A Schwab; Loren Hizel; Daniel Ramon; Babette Brumback; Mingzhou Ding; Catherine C Price
Journal:  Brain Imaging Behav       Date:  2018-02       Impact factor: 3.978

7.  Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations.

Authors:  Jennifer G Goldman; Glenn T Stebbins; Vy Dinh; Bryan Bernard; Doug Merkitch; Leyla deToledo-Morrell; Christopher G Goetz
Journal:  Brain       Date:  2014-01-29       Impact factor: 13.501

8.  Imaging changes associated with cognitive abnormalities in Parkinson's disease.

Authors:  Yuko Koshimori; Barbara Segura; Leigh Christopher; Nancy Lobaugh; Sarah Duff-Canning; Romina Mizrahi; Clement Hamani; Anthony E Lang; Kelly Aminian; Sylvain Houle; Antonio P Strafella
Journal:  Brain Struct Funct       Date:  2014-05-13       Impact factor: 3.270

9.  Hippocampal head atrophy predominance in Parkinson's disease with hallucinations and with dementia.

Authors:  Naroa Ibarretxe-Bilbao; Blanca Ramírez-Ruiz; Eduardo Tolosa; María Jose Martí; Francesc Valldeoriola; Nuria Bargalló; Carme Junqué
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

Review 10.  Hallucinations in Parkinson disease.

Authors:  Nico J Diederich; Gilles Fénelon; Glenn Stebbins; Christopher G Goetz
Journal:  Nat Rev Neurol       Date:  2009-06       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.